Sichuan Kelun Pharmaceutical Co Ltd

Sichuan Kelun Pharmaceutical Co Ltd maintains a market price of 31.38 CNY, with a market capitalization of 49.92 billion CNY and a price-to-earnings ratio of 29.33, indicating a premium valuation relative to earnings. The company's price-to-book ratio of 2.06 suggests that the market values the company at more than double its book value. The enterprise value to EBITDA ratio of 20.95 and enterprise value to revenue ratio of 2.92 reflect a moderate valuation relative to operating performance and revenue. The company's profitability is reflected in a return on equity of 7.03% and a return on assets of 4.27%, both of which are below the typical thresholds for high-performing pharmaceutical firms. The gross profit margin of 47.24% (calculated from gross profit of 8.75 billion CNY on revenue of 18.51 billion CNY) is in line with industry norms, but the operating margin of 14.0% (calculated from operating income of 2.58 billion CNY) is relatively modest, indicating potential inefficiencies in cost control or pricing power. The company's revenue is distributed across three segments: Chuanning, Botai, and Other Business. The Chuanning segment focuses on pharmaceutical intermediates, while the Botai segment is dedicated to innovative drug development. The Other Business segment includes large-volume injections and other pharmaceutical products. The geographic exposure is primarily domestic, with limited overseas operations, as disclosed in the company's segmental breakdown. Looking ahead, the company is projected to see a modest growth trajectory, with analysts forecasting a mean price target of 41.14 CNY, a median of 44.51 CNY, and a high of 46.44 CNY. The mean recommendation of 2.12 suggests a generally positive outlook, with three strong-buy ratings and two buy ratings. The company's revenue history shows a stable but not explosive growth pattern, with a current FY outlook that is neutral to slightly positive. The company faces a medium liquidity risk, as indicated by its current ratio of 2.18 and a negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential in the near term. The company's capital structure includes 4.21 billion CNY in long-term debt and 8.62 million CNY in cash and equivalents, suggesting a relatively conservative leverage profile. Recent events include the publication of the latest financial snapshot and analyst estimates, which provide a comprehensive view of the company's current financial health and market expectations. The company has not disclosed any major recent filings or transcripts that would significantly alter the current assessment of its business or financial position.